Q-omics provides the consensus-scored SEC22B3P profile across patient tissues and cancer cell-line models. SEC22B3P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SEC22B3P is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, SEC22B3P RNA expression shows 5,465 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KICH, and THYM as cancer lineages where SEC22B3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC22B3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC22B3P survival associations across molecular data types. SEC22B3P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC22B3P RNA expression–survival associations across cancer types. High SEC22B3P expression shows unfavorable associations in CESC, SKCM, READ, LIHC and KICH, but favorable associations in GBM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SEC22B3P RNA expression.
This table summarizes SEC22B3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SEC22B3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC22B3P shows lower tumor expression in KICH and THCA. The KICH box plot shows higher SEC22B3P RNA expression in normal versus tumor tissue (log2 FC = −0.068, t-test p = .020).
This table shows molecular features associated with SEC22B3P in patient tissues and cancer cell lines. In patient samples, SEC22B3P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
